Ocrevus Zunovo
Ocrevus Zunovo ingredients
| Active ingredient | Strength |
|---|---|
| Ocrelizumab | 920 mg/23mL |
| Hyaluronidase (Human Recombinant) | 23000 U/23mL |
What Ocrevus Zunovo is used for
The FDA lists the approved uses on the official label (below). In the EU, ocrelizumab is approved as Ocrevus for:
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ocrevus Zunovo
- Generic name
- Ocrelizumab and hyaluronidase
- Made by
- Genentech, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- CD20-directed Cytolytic Antibody, Endoglycosidase
- FDA approval
- Biologic licence (BLA) BLA761371
- On the US market since
- 2024
Official information
- MedlinePlus drug information (search for Ocrelizumab and hyaluronidase)
In India
- Hyaluronidase (human recombinant): 7 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ocrevus Zunovo?
Ocrevus Zunovo (Ocrelizumab and hyaluronidase) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Ocrevus Zunovo?
Ocrevus Zunovo contains Ocrelizumab (920 mg/23mL); Hyaluronidase (Human Recombinant) (23000 U/23mL).
Is Ocrevus Zunovo approved in Europe?
The same active substance is approved in the EU as Ocrevus.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA